Objective-To determine whether a combination viral vaccine containing a modified-live bovine herpesvirus-1 (BHV-1) would protect calves from infection with virulent field strains of BHV-1 for weeks or months after vaccination Design-Randomized controlled trial, performed in 2 replicates. Animals-63 weaned 4- to 6-month-old crossbred beef calves seronegative for antibody against BHV-1. Procedures-Calves were randomly allocated to 1 of 2 treatment groups. Control calves (n = 10/replicate) received a combination modified-live mixed viral vaccine without BHV-1 and treatment calves (20 and 23/replicate) received a combination modified-live mixed viral vaccine containing BHV-1. Each group was challenged via aerosol with 1 of 2 field strains of BHV-1, 30 days after vaccination in replicate 1 and 97 days after vaccination in replicate 2. After challenge, calves were commingled in 1 drylot pen. Clinical signs, immune responses, and nasal shedding of virus were monitored for 10 days after challenge, after which the calves were euthanatized and tracheal lesions were assessed. Results-Vaccination stimulated production of BHV-1-specific IgG antibody that cross-neutralized several field and laboratory strains of BHV-1. Challenge with both field strains of BHV-1 resulted in moderate to severe respiratory tract disease in control calves. Treatment calves had significantly fewer signs of clinical disease, shed less BHV-1, had less or no weight loss after challenge, and had fewer tracheal lesions than control calves for at least 97 days after vaccination. Conclusions and Clinical Relevance-Administration of the combination modified-live BHV-1 vaccine yielded significant disease-sparing effects in calves experimentally infected with virulent field strains of BHV-1.
|Original language||English (US)|
|Number of pages||10|
|Journal||Journal of the American Veterinary Medical Association|
|State||Published - Sep 1 2009|
ASJC Scopus subject areas